Whitegate Investment Counselors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $231K | Buy |
1,061
+101
| +11% | +$22.4K | 0.07% | 61 |
|
|
2025
Q4 | $219K | Hold |
960
| – | – | 0.07% | 62 |
|
|
2025
Q3 | $222K | Buy |
+960
| New | +$195K | 0.07% | 61 |
|
|
2025
Q2 | – | Sell |
-960
| Closed | -$201K | – | 68 |
|
|
2025
Q1 | $201K | Sell |
960
-700
| -42% | -$136K | 0.07% | 62 |
|
|
2024
Q4 | $295K | Hold |
1,660
| – | – | 0.1% | 58 |
|
|
2024
Q3 | $328K | Hold |
1,660
| – | – | 0.09% | 55 |
|
|
2024
Q2 | $285K | Buy |
1,660
+150
| +10% | +$24.8K | 0.08% | 56 |
|
|
2024
Q1 | $275K | Sell |
1,510
-300
| -17% | -$51.7K | 0.08% | 53 |
|
|
2023
Q4 | $280K | Hold |
1,810
| – | – | 0.09% | 53 |
|
|
2023
Q3 | $270K | Sell |
1,810
-100
| -5% | -$14.7K | 0.09% | 51 |
|
|
2023
Q2 | $257K | Sell |
1,910
-50
| -3% | -$7.33K | 0.08% | 52 |
|
|
2023
Q1 | $312K | Hold |
1,960
| – | – | 0.1% | 51 |
|
|
2022
Q4 | $317K | Hold |
1,960
| – | – | 0.11% | 51 |
|
|
2022
Q3 | $263K | Hold |
1,960
| – | – | 0.1% | 52 |
|
|
2022
Q2 | $300K | Hold |
1,960
| – | – | 0.11% | 50 |
|
|
2022
Q1 | $318K | Hold |
1,960
| – | – | 0.1% | 51 |
|
|
2021
Q4 | $265K | Sell |
1,960
-35,213
| -95% | -$4.16M | 0.08% | 53 |
|
|
2021
Q3 | $4.01M | Buy |
37,173
+1,571
| +4% | +$180K | 0.57% | 51 |
|
|
2021
Q2 | $4.01M | Buy |
35,602
+541
| +2% | +$60.9K | 0.57% | 51 |
|
|
2021
Q1 | $3.79M | Buy |
35,061
+1,077
| +3% | +$115K | 0.58% | 53 |
|
|
2020
Q4 | $3.64M | Buy |
33,984
+1,601
| +5% | +$154K | 0.59% | 51 |
|
|
2020
Q3 | $2.84M | Buy |
32,383
+262
| +0.8% | +$24.7K | 0.52% | 55 |
|
|
2020
Q2 | $3.15M | Buy |
32,121
+781
| +2% | +$68.8K | 0.63% | 47 |
|
|
2020
Q1 | $2.39M | Sell |
31,340
-1,787
| -5% | -$152K | 0.58% | 57 |
|
|
2019
Q4 | $2.93M | Sell |
33,127
-293
| -0.9% | -$24.3K | 0.53% | 64 |
|
|
2019
Q3 | $2.53M | Buy |
33,420
+1,667
| +5% | +$114K | 0.5% | 68 |
|
|
2019
Q2 | $2.31M | Buy |
31,753
+3,995
| +14% | +$314K | 0.46% | 71 |
|
|
2019
Q1 | $2.24M | Sell |
27,758
-730
| -3% | -$59.7K | 0.46% | 70 |
|
|
2018
Q4 | $2.63M | Sell |
28,488
-110
| -0.4% | -$9.67K | 0.61% | 60 |
|
|
2018
Q3 | $2.71M | Sell |
28,598
-440
| -2% | -$41.7K | 0.55% | 63 |
|
|
2018
Q2 | $2.69M | Sell |
29,038
-175
| -0.6% | -$17.1K | 0.55% | 63 |
|
|
2018
Q1 | $2.77M | Sell |
29,213
-1,505
| -5% | -$165K | 0.59% | 58 |
|
|
2017
Q4 | $2.97M | Sell |
30,718
-546
| -2% | -$51.5K | 0.62% | 57 |
|
|
2017
Q3 | $2.78M | Sell |
31,264
-11,539
| -27% | -$878K | 0.61% | 60 |
|
|
2017
Q2 | $3.1M | Buy |
42,803
+400
| +0.9% | +$26.9K | 0.7% | 47 |
|
|
2017
Q1 | $2.76M | Sell |
42,403
-650
| -2% | -$40.9K | 0.66% | 58 |
|
|
2016
Q4 | $2.7M | Sell |
43,053
-1,427
| -3% | -$87.1K | 0.72% | 50 |
|
|
2016
Q3 | $2.81M | Buy |
44,480
+1,474
| +3% | +$95.4K | 0.76% | 45 |
|
|
2016
Q2 | $2.66M | Buy |
+43,006
| New | +$2.62M | 0.74% | 42 |
|
|
2014
Q1 | $2.53M | Buy |
+44,230
| New | +$2.24M | 0.69% | 48 |
|
Other funds holding ABBV
VCM
VPM
Whitegate Investment Counselors's ABBV Position: Q1 2026 in Review
Whitegate Investment Counselors increased its AbbVie (ABBV) stake by 11% in Q1 2026, buying an estimated $22.4K and bringing the position to 1,061 shares worth $231K. The position accounts for 0.07% of the portfolio, ranked #61.
Whitegate Investment Counselors first reported a position in ABBV in Q1 2014 and has held it in 40 quarters since. The position peaked at $4.01M in Q3 2021. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Whitegate Investment Counselors held 1,061 shares of AbbVie worth $231K as of Q1 2026.
- Whitegate Investment Counselors bought 101 AbbVie shares in Q1 2026, an estimated $22.4K.
- AbbVie made up 0.07% of Whitegate Investment Counselors's portfolio in Q1 2026, its #61 holding.
- Whitegate Investment Counselors first reported a position in AbbVie in Q1 2014 and has held it in 40 quarters since.
- Whitegate Investment Counselors's AbbVie position peaked at $4.01M in Q3 2021.
- 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Whitegate Investment Counselors's 13F filing for Q1 2026, filed 27 Apr 2026.